On September 3, 2025, Mesoblast Limited, a leading global provider of allogeneic cellular medicines for inflammatory diseases, announced that it has signed convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck. The company is set to issue unsecured convertible notes worth up to US$50.0 million (A$76.8 million) to the investors. This funding can be utilized by Mesoblast, upon shareholder approval, to repay or lessen the debt owed to its secured lenders as per existing loan agreements, as well as for general working capital purposes.